Matrix Metalloproteinases and Blood-Brain Barrier Disruption in Acute Ischemic Stroke
Open accessThe DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Abstract
Ischemic stroke continues to be one of the most challenging diseases in translational neurology. Tissue plasminogen activator (tPA) remains the only approved treatment for acute ischemic stroke, but its use is limited to the first hours after stroke onset due to an increased risk of hemorrhagic transformation over time resulting in enhanced brain injury. In this review we discuss the role of matrix metalloproteinases (MMPs) in blood-brain barrier (BBB) disruption as a consequence of ischemic stroke. MMP-9 in particular appears to play an important role in tPA-associated hemorrhagic complications. Reactive oxygen species can enhance the effects of tPA on MMP activation through the loss of caveolin-1 (cav-1), a protein encoded in the cav-1 gene that serves as a critical determinant of BBB permeability. This review provides an overview of MMPs' role in BBB breakdown during acute ischemic stroke. The possible role of MMPs in combination treatment of acute ischemic stroke is also examined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue Plasminogen Activator for Acute Ischemic Stroke
(1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332401 · Cited by 11,654
Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke
Hacke, W., Kaste, M., Bluhmki, E., Brozman, M., Dávalos, A., Guidetti, D., Larrue, V., Lees, K. R., Medeghri, Z., Machnig, T., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804656 · Cited by 6,684 · cited 1×
“For acute ischemic stroke, thrombolysis is beneficial for patients if induced during the first 3–4.5 h of symptom onset (NINDS, ECASS III) (National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, 1995; Hacke et al., 2008).”
InfluentialStructure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185 · cited 1×
“Although disruption of AJs at the BBB can lead to increased permeability, it is primarily the TJ that confers low paracellular permeability and high electrical resistance (Abbruscato and Davis, 1999).”
How Matrix Metalloproteinases Regulate Cell Behavior
Sternlicht, M. D., & Werb, Z. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.463 · Cited by 3,959 · cited 1×
“An alternate classification arranges the MMPs according to their domain structure (Sternlicht and Werb, 2001).”
Pathobiology of ischaemic stroke: an integrated view
Dirnagl, U., Iadecola, C., & Moskowitz, M. A. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(99)01401-0 · Cited by 3,943 · cited 1×
“This ultimately causes irreversible neuronal injury in the ischemic core within minutes of the onset (Dimagl et al., 1999).”
Ghrelin: Structure and Function
Kojima, M., & Kangawa, K. (2005) · Physiological Reviews · doi:10.1152/physrev.00012.2004 · Cited by 2,810
The blood-brain barrier/neurovascular unit in health and disease
Hawkins, B. T., & Davis, T. P. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.4 · Cited by 2,661 · cited 4×
“Essentially, all members of the MMP family have been linked to disease development, notably to cancer metastasis, chronic inflammation with ensuing tissue damage, as well as to neurological disorders (for review see Klein and Bischoff, 2011). that is essential for the health and function of the CNS (Hawkins and Davis,…”
InfluentialMechanisms, challenges and opportunities in stroke
Lo, E. H., Dalkara, T., & Moskowitz, M. A. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1106 · Cited by 1,781
Inflammatory mechanisms in ischemic stroke: role of inflammatory cells
Jin, R., Yang, G., & Li, G. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.1109766 · Cited by 1,521
Tissue inhibitors of metalloproteinases: structure, regulation and biological functions.
Gomez, D. E., Alonso, D. F., Yoshiji, H., & Thorgeirsson, U. P. (1997) · PubMed · Cited by 1,508
Cited by
Neuroinflammation: friend and foe for ischemic stroke
Jayaraj, R. L., Azimullah, S., Beiram, R., Jalal, F. Y., & Rosenberg, G. A. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1516-2 · Cited by 1,428
Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions
Qin, C., Yang, S., Chu, Y.-H., Zhang, H., Pang, X.-W., Chen, L., Zhou, L.-Q., Chen, M., Tian, D.-S., & Wang, W. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01064-1 · Cited by 939
Current advances in ischemic stroke research and therapies
Barthels, D., & Das, H. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.09.012 · Cited by 709
Knowland, D., Arac, A., Sekiguchi, K. J., Hsu, M., Lutz, S. E., Perrino, J., Steinberg, G. K., Barres, B. A., Nimmerjahn, A., & Agalliu, D. (2014) · Neuron · doi:10.1016/j.neuron.2014.03.003 · Cited by 703
“derived matrix metalloproteinases (MMPs), release of inflammatory cytokines within the ischemic core or peri-infarct area and secretion of vascular endothelial growth factor (VEGF) have all been postulated to trigger TJ disassembly during reperfusion (Rosenberg and Yang, 2007; Arai et al., 2011; Lakhan et al., 2013).”
Health benefits of resveratrol: Evidence from clinical studies
Singh, A. P., Singh, R., Verma, S. S., Rai, V., Kaschula, C. H., Maiti, P., & Gupta, S. C. (2019) · Medicinal Research Reviews · doi:10.1002/med.21565 · Cited by 523
Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke
Montaner, J., Ramiro, L., Simats, A., Tiedt, S., Makris, K., Jickling, G. C., Debette, S., Sanchez, J.-C., & Bustamante, A. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0350-6 · Cited by 330
MMP-9 Inhibition: a Therapeutic Strategy in Ischemic Stroke
Chaturvedi, M., & Kaczmarek, L. (2014) · Molecular Neurobiology · doi:10.1007/s12035-013-8538-z · Cited by 296
Exosomes as a Nanodelivery System: a Key to the Future of Neuromedicine?
Aryani, A., & Denecke, B. (2016) · Molecular Neurobiology · doi:10.1007/s12035-014-9054-5 · Cited by 238
“leakage [147].”
Brkic, M., Balusu, S., Libert, C., & Vandenbroucke, R. E. (2015) · Mediators of Inflammation · doi:10.1155/2015/620581 · Cited by 205
“MMP inhibitors yielded beneficial results in animal studies of lung inflammatory diseases [282], multiple sclerosis [265], meningitis [283–285], vascular dementia [52], stroke [286], acute cerebral ischemia [287, 288], and sepsis [1, 15, 289, 290].”
Blood-Brain Barrier Protection as a Therapeutic Strategy for Acute Ischemic Stroke
Sifat, A. E., Vaidya, B., & Abbruscato, T. J. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0091-7 · Cited by 171
Platt, M. P., Agalliu, D., & Cutforth, T. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00442 · Cited by 108
Breaking boundaries—coagulation and fibrinolysis at the neurovascular interface
Bardehle, S., Rafalski, V. A., & Akassoglou, K. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00354 · Cited by 76
Wilk, C. M., Cathomas, F., Török, O., Le Berichel, J., Park, M. D., Bigenwald, C., Heaton, G. R., Hamon, P., Troncoso, L., Scull, B. P., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.11.011 · Cited by 51
Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's Disease
Reich, N., & Hölscher, C. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.614828 · Cited by 48
“, 2014a), the MMP family member that directly proteolyzes BBB components (Lakhan et al., 2013).”
BackgroundChen, F., Weng, Z., Xia, Q., Cao, C., Leak, R. K., Han, L., Xiao, J., Graham, S. H., & Cao, G. (2019) · Translational Stroke Research · doi:10.1007/s12975-019-00692-0 · Cited by 31
Liu, C., Sun, S., Xie, J., Li, H., Li, T., Wu, Q., Zhang, Y., Bai, X., Wang, J., Wang, X., et al. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02811-9 · Cited by 28
Blood brain barrier inflammation and potential therapeutic role of phytochemicals
Welcome, M. O. (2020) · PharmaNutrition · doi:10.1016/j.phanu.2020.100177 · Cited by 22
Metadata
- Authors
- Lakhan, S. E., Kirchgessner, A., Tepper, D., & Leonard, A.
- Venue
- Frontiers in Neurology
- Publisher
- Frontiers Media SA
- Published
- 2013
- Volume
- 4
- Pages
- 32-32
- ISSN
- 1664-2295 (ISSN-L)
- OpenAlex
- W2160213908
- Cited by
- 384
- References
- 144
- FWCI
- 11.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.